To promote patient access to expensive essential medicines, there has been growing interest in government purchasing of drugs that could then be made widely available. We will examine two case studies of this approach (direct-acting antivirals for hepatitis C virus, and pre-exposure prophylaxis for HIV prevention) to understand how these programs work and how they navigate patents, drug regulations, and public health law.
Speakers:
- Dr. Joshua Sharfstein, Vice Dean for Public Health Practice and Community Engagement, director of the Bloomberg American Health Initiative, and Professor of the Practice in Health Policy and Management, Johns Hopkins Bloomberg School of Public Health
- Aaron Kesselheim, Professor of Medicine at Harvard Medical School, faculty of the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women’s Hospital, Visiting Professor of Law and Solomon Center Distinguished Visitor at Yale Law School
- Rena Conti, Dean’s Research Scholar, Associate Professor of Markets, Public Policy, and Law at the Boston University Questrom School of Business
Amy Killela, Owner of Killela Consulting; Senior Associate in the Health Policy and Management Program at the Johns Hopkins Bloomberg School of Public Health
Sponsoring Organization(s)
Solomon Center for Health Law and Policy